CymaBay Therapeutics in the NEWS
CymaBay Therapeutics (CBAY) today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC).

Seladelpar is a first-in-class oral, selective PPARδ agonist being investigated for the treatment of patients with primary . . .